A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Topical Corticosteroids

A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2008.02716.x ◽

2008 ◽

Vol 22 (9) ◽

pp. 1076-1082 ◽

Cited By ~ 25

Author(s):

MLA Schuttelaar ◽

PJ Coenraads

Keyword(s):

Atopic Dermatitis ◽

Triamcinolone Acetonide ◽

Blind Study ◽

Double Blind Study ◽

Double Blind

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Topical Corticosteroids

Abstract not available.

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

10.25251/skin.4.supp.102 ◽

2020 ◽

Vol 4 (6) ◽

pp. s102

Author(s):

Stephan Weidinger ◽

Jonathan Silverberg ◽

Darryl Toth ◽

Thomas Bieber ◽

Andrew Alexis ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Topical Corticosteroids

Abstract not available.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00589-4 ◽

2021 ◽

Cited By ~ 1

Author(s):

Kristian Reich ◽

Henrique D Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

10.25251/skin.1.supp.81 ◽

2017 ◽

Vol 1 ◽

pp. s82

Author(s):

Steven Dayan ◽

Patricia Ogilvie ◽

Alexander Z Rivkin ◽

Steven G Yoelin ◽

Julie K Garcia ◽

...

Keyword(s):

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Patient Reported

Abstract Not Available Disclosures: Study supported by Allergan.

Faculty Opinions recommendation of A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1120013.576136 ◽

2008 ◽

Author(s):

Arnold Oranje

Keyword(s):

Atopic Dermatitis ◽

Clinical Efficacy ◽

Blind Study ◽

Double Blind Study ◽

Silk Fabric ◽

Double Blind

Efficacy and Tolerability of Lasmiditan, an Oral 5-HT1F Receptor Agonist, for the Acute Treatment of Migraine: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study

SSRN Electronic Journal ◽

10.2139/ssrn.3228912 ◽

2018 ◽

Author(s):

Peter Goadsby ◽

Linda Wietecha ◽

Ellen Dennehy ◽

Bernice Kuca ◽

Michael Case ◽

...

Keyword(s):

Acute Treatment ◽

Receptor Agonist ◽

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind